Background
==========

Merkel cell carcinoma (MCC) is a rare but aggressive neuroendocrine skin carcinoma with an annual incidence of approximately 2500 cases in the United States, which is increasing \[[@b1-amjcaserep-19-505]--[@b3-amjcaserep-19-505]\]. Eighty percent of MCC tumors are associated with the Merkel cell polyomavirus (MCPyV) \[[@b4-amjcaserep-19-505]\]. Staging is predictive of survival, with 5-year overall survival for local, nodal, and distant disease at 51%, 35%, and 14%, respectively \[[@b5-amjcaserep-19-505]\].

In patients with distant metastatic disease, the median survival from the time of initial metastasis is approximately 10 months \[[@b6-amjcaserep-19-505]\]. Metastatic MCC is generally treated with cytotoxic chemotherapy, commonly with platinum-based agents plus etoposide, as first-line therapy. Although cytotoxic chemotherapy has a high (\>50%) objective response rate (ORR), responses are seldom durable; the median progression-free survival (PFS) is a modest 94 days \[[@b7-amjcaserep-19-505]--[@b9-amjcaserep-19-505]\]. The response rate for second-line cytotoxic chemotherapy is much lower (23%), with a median PFS of only 61 days \[[@b9-amjcaserep-19-505]\].

Recent prospective clinical trials have demonstrated promising efficacy of programmed death 1 (PD-1) and programmed death ligand 1 (PD-L1) inhibitors in advanced MCC. In the first-line setting, ORRs for pembrolizumab, avelumab, and nivolumab were 56% (14/26 patients) \[[@b10-amjcaserep-19-505]\], 62% (24/39) \[[@b11-amjcaserep-19-505]\], and 73% (11/15) \[[@b12-amjcaserep-19-505]\], respectively. In the chemotherapy-refractory setting, avelumab had an ORR of 31.8% (28/88 patients) \[[@b13-amjcaserep-19-505]\]. Responses were strikingly durable in these trials. However, a considerable proportion of patients with metastatic MCC do not respond to PD-1/PD-L1 blockade. Many patients are not candidates for immunotherapy due to autoimmune or immunosuppressive comorbid conditions. Hence, there is still an unmet need for other therapeutic options in this disease.

While the rationale for immunotherapy in MCC has been well described, there has been little success in identifying tumor-signaling pathways amenable to molecular targeting in MCC \[[@b14-amjcaserep-19-505]\]. There is increasing evidence supporting the importance of angiogenesis in the pathogenesis of MCC. Cutaneous MCC tumors frequently have a characteristic appearance suggestive of increased vascularity ([Figure 1](#f1-amjcaserep-19-505){ref-type="fig"}). There is evidence of prominent vascular proliferation in up to 20% of MCC tumors, which appears to be a shared feature across many neuroendocrine tumors \[[@b15-amjcaserep-19-505]\]. MCC tumors have expression of vascular endothelial growth factor (VEGF)-A, VEGF-C, VEGF-R2, and platelet-derived growth factor (PDGF)-b in 91%, 75%, 88%, and 72% of tumors, respectively \[[@b16-amjcaserep-19-505]\]. Up to 80--90% of MCC tumors express platelet-derived growth factor receptor (PDGFR)-A \[[@b17-amjcaserep-19-505],[@b18-amjcaserep-19-505]\]. MCC tumors have also been shown to express c-kit \[[@b19-amjcaserep-19-505]--[@b22-amjcaserep-19-505]\]. One study showed a positive correlation between tumor size and vascular endothelial growth factor receptor (VEGFR)-2 expression, with 91% of tumors ≥2.0 cm expressing VEGFR-2 *vs.* 70% of tumors \<2.0 cm \[[@b23-amjcaserep-19-505]\]. This evidence supports the potential utility of anti-angiogenic drugs in this aggressive disease.

Pazopanib and cabozantinib are inhibitors of multiple receptor tyrosine kinases, (VEGFR)-1, -2, and -3 and Kit. Pazopanib also inhibits (PDGFR)-α and -β. There is minimal published clinical data on their utility in MCC. A single case report demonstrated 6 months of clinical benefit from pazopanib in a patient with metastatic MCC after treatment with multiple rounds of chemotherapy \[[@b24-amjcaserep-19-505]\]. There was a mutation in PDGFR-α gene and expression of VEGF, giving a possible explanation for the response \[[@b24-amjcaserep-19-505]\]. To add to this literature, we describe a case series of successful use of VEGFR-tyrosine kinase inhibitors (TKIs) in 5 patients with metastatic MCC ([Table 1](#t1-amjcaserep-19-505){ref-type="table"}). These patients were selected from a total of 24 patients with metastatic MCC who were treated with TKIs standardly (i.e., not on an investigational protocol) due to lack of other treatment options. We have selected these 5 cases to highlight the potential utility of these agents in different clinical scenarios. All studies were performed in accordance with Helsinki principles and were approved by the Institutional Review Board at the Fred Hutchinson Cancer Research Center (IRB \#6585). All patients included in this study had provided informed consent for their clinical data to be analyzed for research purposes.

Case Reports
============

Patient 1
---------

A 58-year-old man presented with a left calf primary MCC tumor and lower-extremity edema. A staging FDG PET-CT scan revealed widely disseminated MCC involving multiple (popliteal, inguinal, periaortic, and retroperitoneal) lymph nodes, cutaneous metastases, and liver metastases. He had a history of severe, symptomatic psoriatic arthritis, which had required treatment with several systemic immunosuppressive drugs, including methotrexate, efalizumab, etanercept, and adalimumab over the past 3 years. He received single-fraction high-dose (8 Gray) radiation therapy to the bulky inguinal and retroperitoneal lymph nodes, with rapid palliation of his lower-extremity edema. He received pazopanib 800 mg daily and noticed regression of cutaneous metastases within 2 weeks of starting therapy. Restaging FDG PET-CT scan 2 weeks after starting pazopanib showed interval improvement of hypermetabolic metastatic sites. He also had marked improvement in his arthritis and was able to discontinue systemic immunosuppression throughout the duration of pazopanib therapy. He continued to receive pazopanib for 5 months, before he developed disease progression at nodal sites for which he was treated with combination pazopanib and octreotide for 3 months. He developed metastases in the pancreas and died weeks later despite receiving carboplatin plus etoposide.

Patient 2
---------

A 65-year-old man presented with syncopal episodes related to compression of the superior vena cava from extensive and bulky (up to 10 cm in size) lymphadenopathy involving supraclavicular, mediastinal, and paratracheal lymph nodes. A biopsy of the left supraclavicular lymph node revealed MCC with no evidence of a primary cutaneous tumor. He initially received 6 cycles of carboplatin plus etoposide and concurrent radiation therapy (36 Gy) to mediastinal and supraclavicular lymph nodes, with initial regression of all tumors. Three months after the last cycle of chemotherapy, he had progressive disease at several new lymph nodes in the chest. He received pazopanib 800 mg daily and developed hepatic toxicity, which improved with dose reduction to 400 mg daily and did not recur with subsequent cautious dose escalation to 600 mg daily. Three months after starting pazopanib, a restaging FDG PETCT scan showed complete resolution of previously FDG-avid lymph nodes in the chest (right hilar, right paratracheal, mediastinal, prevascular, and subcarinal lymph nodes, [Figure 2](#f2-amjcaserep-19-505){ref-type="fig"}). He received pazopanib for 14 months before developing significant progressive disease in abdominal and retroperitoneal lymph nodes. He then received treatment with single-fraction high-dose radiation and depot octreotide acetate injections for 10 months before dying due to obstructive jaundice from pancreatic metastases.

Patient 3
---------

A 75-year-old man was diagnosed with MCC of the right posterior scalp, which was treated with wide excision. Shortly after the excision, he developed recurrent disease with enlarged right cervical and supraclavicular lymph nodes. He received 4 cycles of carboplatin plus etoposide chemotherapy and concurrent radiation therapy to the primary tumor bed (60 Gy) and right neck (64 Gy), with a complete response to therapy. Thirteen months later, he developed progressive disease in cervical and inguinal lymph nodes. He received 6 cycles of topotecan, with a mixed response. A restaging PET-CT at 3 months after topotecan ended revealed progressive disease in cervical, bilateral axillary, subpectoral, retroperitoneal, iliac, and inguinal lymph nodes. He also developed a metastatic lesion in the right frontal lobe of the brain, treated with surgery and radiation. He then received pazopanib 800 mg daily. Four months after therapy, a restaging PET-CT revealed decreased FDG avidity at known sites of disease. Three months later, mild progression of disease was noted on restaging scans. An OctreoScan suggested somatostatin receptor expression on MCC tumors, and once-monthly depot octreotide acetate injections were administered concurrently with pazopanib. He tolerated this combination and continued treatment for another 16 months before he died due to progressive disease.

Patient 4
---------

A 61-year-old man presented with a primary MCC tumor on the right lower back and extensive metastatic disease involving the pancreas, multiple intra-abdominal soft tissue masses, and a 9-cm tumor in the splenic hilum. He was treated with carboplatin plus etoposide chemotherapy, with an initial response after 2 cycles of therapy. He developed progressive disease after the 4th cycle of chemotherapy. He then received 2 cycles of topotecan, but a restaging PET-CT scan revealed significant progression of tumors. He received single-fraction high-dose (6--8 Gy) radiation therapy (RT) to some of the bulky metastatic sites, followed by initiation of pazopanib 800 mg/day 1 month after RT. Restaging scans 2 and 4 months after initiation of pazopanib revealed decreased avidity and size of various metastatic sites without any new lesions. He was progression-free for a total of 7 months after initiation of pazopanib, before he developed progressive disease and died. The PFS of 7 months with pazopanib was longer than the progression-free interval with first- and second-line chemotherapy regimens.

Patient 5
---------

A 69-year-old man presented with an enlarged left supraclavicular lymph node, and biopsy revealed MCC. Staging PET-CT showed mediastinal, retroperitoneal, and pelvic lymphadenopathy. Biopsy of a left periaortic lymph node and right supraclavicular lymph node confirmed metastatic MCC. A primary cutaneous tumor was not identified. He received 5 cycles of chemotherapy (cisplatin plus etoposide) with an initial partial response. Four months after starting chemotherapy, progression was noted in retroperitoneal lymph nodes. He initially received cabozantinib, 60 mg daily. This dose was decreased to 40 mg 5 days a week due to diarrhea, abdominal cramping, and hypertension. He received cabozantinib for 21 months total before it was stopped due to development of muscle weakness in the lower extremities, with concern for rhabdomyolysis. The symptoms were attributed to spinal stenosis. Despite discontinuation of cabozantinib, he remained progression-free for approximately 3.5 years after starting cabozantinib, before he developed recurrence in the left supraclavicular lymph node. He is currently receiving treatment with nivolumab and RT, with an encouraging initial clinical response. The prolonged disease control associated with cabozantinib has enabled bridging to immunotherapy, which was not available for MCC treatment at the time of his initial presentation.

Discussion
==========

In this case series, we describe the successful use of VEGFRTKIs, pazopanib and cabozantinib, in 5 patients with metastatic MCC. These patients, who had previously received cytotoxic chemotherapy and did not have access to immunotherapy trials, experienced prolonged disease control for several months, with good tolerability. This report highlights the possibility of clinical benefit with VEGFR TKIs in this aggressive cancer.

There are many limitations to this report. These 5 cases were selected from a total of 24 patients treated with VEGRF-TKIs, because of successful clinical outcomes. Therefore, this case series represents a biased portrayal of TKI efficacy and should not be used to estimate the proportion of metastatic MCC patients who could benefit from this approach. This case series is only meant to suggest potential clinical scenarios that could benefit from the use of these drugs in MCC. Efficacy of these agents needs to be studied with prospective clinical trials. Our experience suggests that clinical benefit from these agents should include stable disease as a meaningful endpoint, in addition to objective responses, because several patients in this series had prolonged stabilization of disease without an objective response as defined by RECIST. Since the proportion of patients deriving clinical benefit is unlikely to be high, correlative studies must incorporate exploration of predictive biomarkers to help patient selection. In this series, we were unable to study MCC tumor expression or activating mutations in c-kit or PDGFR to correlate with clinical benefit.

There are prospective clinical trials already underway that are investigating these agents. A single-arm multicenter phase 2 clinical trial in the UK ([clinicaltrialsregister.eu](clinicaltrialsregister.eu); Eudra CT\# 2011-003226-27) is investigating pazopanib in patients with metastatic MCC. Preliminary results from 16 evaluable patients include a partial response rate of 19% (3/16 patients) and a disease control rate (objective response plus stable disease for \>12 weeks) of 56% (9/16) \[[@b25-amjcaserep-19-505]\]. Another trial is investigating cabozantinib ([clinicaltrials.gov](clinicaltrials.gov); NCT02036476) at a single center in the US.

In our series, the duration of benefit from pazopanib was longer than that observed with prior chemotherapy regimens in those patients who had received chemotherapy. The use of pazopanib was associated with improved arthritic symptoms in patient \#1 and allowed discontinuation of immune suppression. Angiogenic mechanisms are relevant in pathophysiology of inflammatory arthritis, and the anti-angiogenic effects of VEGFR-TKIs may be beneficial in these patients with MCC \[[@b26-amjcaserep-19-505]\]. Typically, immunosuppressed patients with MCC have dismal outcomes \[[@b27-amjcaserep-19-505]\], and the discontinuation of immune suppression in arthritic patients could potentially improve MCC outcomes. The duration of clinical benefit from VEGFR-TKIs can be used as a bridge towards standard or investigational immunotherapy by stabilizing the disease. Unlike cytotoxic chemotherapy, anti-angiogenic therapy is not thought to be immune-suppressive. These agents may improve the efficacy of immunotherapy by modulating the tumor microenvironment through reduction of immune suppressive cytokines and regulatory T cells \[[@b28-amjcaserep-19-505],[@b29-amjcaserep-19-505]\].

MCC, a neuroendocrine cancer, commonly expresses somatostatin receptors \[[@b30-amjcaserep-19-505]\]. In 2 patients (\#2 and \#3), the duration of benefit from VEGFR-TKIs was prolonged by addition of long-acting octreotide agents in patients whose tumors expressed somatostatin receptors. Patient \#3 received pazopanib in combination with octreotide acetate, with stabilization of disease for an additional 16 months. The favorable toxicity profile of VEGFR-TKIs and somatostatin analogues supports the safety of combining the 2 modalities. Two patients (\#1 and \#4) received single-fraction high-dose radiation to bulky tumors for disease stabilization prior to starting pazopanib. Single-fraction high-dose radiation can be used for debulking large or symptomatic tumors prior to initiation of TKIs \[[@b31-amjcaserep-19-505]\]. Complications have been reported with the concurrent use of radiotherapy with VEGF-TKIs; hence, we recommend caution with the timing of TKIs around RT \[[@b32-amjcaserep-19-505],[@b33-amjcaserep-19-505]\].

Conclusions
===========

In summary, this retrospective case series highlights the potential utility of VEGFR-TKIs in MCC patients. Given the modest benefit with cytotoxic chemotherapy in advanced MCC, VEGFR-TKIs may provide clinical benefit in patients who progressed after PD-1 blockade and/or who were not eligible for the same. Further data from prospective clinical trials are needed to determine the efficacy of TKIs as monotherapy and in combination with immunotherapy.
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![Panel **A** and **B** show large cutaneous MCC tumors on 2 separate patients. MCC tumors generally have a characteristic appearance suggestive of increased vascularity, supporting the importance of angiogenesis in these tumors. (These 2 patients are not included in this case series.)](amjcaserep-19-505-g001){#f1-amjcaserep-19-505}

![Panel **A** represents hypermetabolic paratracheal, subcarinal, hilar, and mediastinal lymph nodes (circles and arrows) in patient \#2 prior to initiation of pazopanib. Panel **B** represents a complete metabolic response of the FDG-avid lymph nodes in the chest after 3 months of therapy with pazopanib.](amjcaserep-19-505-g002){#f2-amjcaserep-19-505}

###### 

Patient characteristics, treatment, and response to TKIs.

  **Patient**   **Age, y/Sex**   **Stage at MCC diagnosis[^\*^](#tfn1-amjcaserep-19-505){ref-type="table-fn"}**   **Time from diagnosis of metastatic disease to TKI therapy**   **Therapies for metastatic disease prior to TKI therapy**   **Sites of metastases at the time of TKI therapy**                                               **TKI used and dose**                                                                                   **Duration of clinical benefit from TKI**   **Treatment after TKI**                                            **Comments**
  ------------- ---------------- -------------------------------------------------------------------------------- -------------------------------------------------------------- ----------------------------------------------------------- ------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------- ------------------------------------------- ------------------------------------------------------------------ ----------------------------------------------------------------------------------------------------------
  1             58/M             IV                                                                               2 months                                                       Single fraction RT                                          Popliteal, inguinal, periaortic, retroperitoneal LNs, liver, cutaneous                           Pazopanib 800 mg/d                                                                                      5 months                                    Combination Pazopanib and Octreotide, Carboplatin plus Etoposide   Improvement of psoriatic arthritis on TKI
  2             65/M             IV, unknown primary                                                              10 months                                                      Carboplatin plus etoposide, RT                              Right paratracheal, right hilum, prevascular, sub carinal LNs                                    Pazopanib 800 mg/d, hepatic toxicity, improved with dose reduction to 400 mg/d, increased to 600 mg/d   14 months                                   Single fraction RT, Octreotide                                     Stabilization of disease for additional 10 months on Octreotide
  3             75/M             IIB                                                                              10 months                                                      Topotecan, craniotomy and RT to brain                       Cervical, b/l axillary, left subpectoral, retroperitoneal, external iliac and b/l inguinal LNs   Pazopanib 800 mg/d                                                                                      7 months                                    Combination Pazopanib and Octreotide                               Stabilization of progressive disease for an additional 16 months on combination Pazopanib and Octreotide
  4             61/M             IV                                                                               6 months                                                       Carboplatin plus Etoposide, Topotecan, single fraction RT   Abdominal and retroperitoneal LNs, pancreas and spleen                                           Pazopanib 800 mg/d, decreased to 400 mg/d                                                               7 months                                    Single fraction RT, Pembrolizumab                                  PFS longer on pazopanib than prior chemotherapy
  5             69/M             IV, unknown primary                                                              6 months                                                       Cisplatin plus Etoposide                                    Retroperitoneal LN                                                                               Cabozantinib, 60 mg/d dose reduced to 40 mg 5 days/week                                                 3.5 years                                   Nivolumab RT                                                       TKI therapy allowed bridging to immunotherapy

American Joint Committee on cancer (AJCC) staging system 7^th^ edition. TKI -- tyrosine kinase inhibitors; MCC -- Merkel cell carcinoma; M -- Male: y -- year; Gy -- gray; RT -- radiation therapy; LN -- lymph nodes; d -- daily; b/l -- bilateral, PFS -- progression free survival.
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